Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring

Trial Profile

A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SWITCH PRO
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 03 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 17 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top